ArkeaBio cuts headcount, banks $15M to carry cattle methane vaccine to market

Boston-based ArkeaBio has raised $15 million in Series A2 funding led by AgriZeroNZ, with support from Breakthrough Energy Ventures, to advance a vaccine designed to reduce methane emissions from cattle and other ruminants. The company's technology works by prompting an animal's immune system to generate antibodies against methane-producing microbes in the rumen, offering a delivery mechanism that fits into existing livestock vaccination routines rather than requiring new daily feeding practices.

The round comes with a significant operational shift. ArkeaBio cut its workforce by roughly one-third while raising the capital, narrowing its focus around New Zealand, its first product, and initial revenue. CEO Frank Wooten said the new capital should carry the company through its first commercial product. The company expects to seek regulatory approval in New Zealand next year and hopes to begin commercial sales in 2028.

The financing lands among several technical approaches to livestock methane, including feed additives, selective breeding, microbiome engineering, and seaweed-based supplements. ArkeaBio's argument is operational: farmers already vaccinate livestock, so a methane-reduction vaccine could fit into an existing workflow. Wooten told AgFunderNews that the first commercial product is targeting methane reductions closer to 10% to 15%, below the reductions claimed by some feed additives, with later generations expected to improve on that.

Those performance and timeline figures remain company projections, and the startup's value ultimately depends on whether the vaccine works, clears regulatory hurdles, and can be adopted economically by livestock producers. The combination of fresh financing and a smaller operating footprint suggests investors are prioritizing runway and commercialization over funding every research program at once.